Etanercept
From Ganfyd
 | Alzheimer? Very early reports of its use intrathecally against Alzheimer's disease have appeared recently. Evaluation is required. |
rINN: Etanercept
Other Names
Enbrel®
Pharmacological Information
Pharmacology Images
Image:EtanerceptMolecule.png
Etanercept Molecule
Etanercept in the:
BNF-registration required
BNF for children-registration required
Relevant Clinical Literature
Systematic reviews from Pubmed
Other Literature
Please read pharmacological data limitations
Contents |
Introduction
A TNF inhibitor used as a treatment for inflammatory arthritis.
Clinical Use
Indications
see manufacturers literature
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Psoriasis
- Polyarticular juvenile idiopathic arthritis
Administration
IV
Clinical Issues
Contra-indications
- Pregnancy
- Active infection
Cautions and Interactions
Side effects
- Hypersensivity
- Fever
- Nausea
- Abdominal pain
- Heart failure
- Headache
- Pruritis
- Depression
- SLE like syndrome
- Blood dyscrasias
- Infections, including severe sepsis (odds ratio for serious infection 2.0 (95% CI, 1.3-3.1), number needed to harm 59 (95% CI, 39-125) within a treatment period of 3 to 12 months).[1]
- Malignancy (odds ratio for malignancy 3.3 (95% CI, 1.2-9.1) number needed to harm 154 (95% CI, 91-500) for 1 additional malignancy within period of 6 to 12 months)[2], including an association with hepatosplenic T-cell lymphoma in patients also on mercaptopurines.[3]
Special advice
Pharmacology
[edit]
References
- ↑ Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA : the journal of the American Medical Association 2006;295(19):2275-85. (Direct link – subscription may be required.)
- ↑ Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA : the journal of the American Medical Association 2006;295(19):2275-85.(Direct link - subscription may be required.)
- ↑ Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? Inflamm Bowel Dis 2007. (Direct link – subscription may be required.)
This article is a work in progress. Please feel free to contribute to it.
